Cyclic HIV-1 protease inhibitors derived from mannitol: Synthesis, inhibitory potencies, and computational predictions of binding affinities

Journal of Medicinal Chemistry

Volumn 40, Issue 6, 1997, Pages 885-897

  Hultén, Johan ^a   Bonham, Nicholas M ^a   Nillroth, Ulrika ^a   Hansson, Tomas ^a   Zuccarello, Guido ^b   Bouzide, Abderrahim ^b   Åqvist, Johan ^a   Classon, Björn ^c   Danielson, U Helena ^a   Karlén, Anders ^a   Kvarnström, Ingemar ^b   Samuelsson, Bertil ^d   Hallberg, Anders ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c MEDIVIR AB   (Sweden)

^d STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4,7 DIBENZYL 2,3,4,5,6,7 HEXAHYDRO 5,6 DIHYDROXY 1,3 BIS[4 (HYDROXYMETHYL)BENZYL] 2H 1,3 DIAZEPIN 2 ONE; MANNITOL; PROTEINASE INHIBITOR; SULFANILAMIDE; UREA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CALCULATION; COMPUTER MODEL; COMPUTER SIMULATION; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; LIGAND BINDING; PREDICTION; STEREOCHEMISTRY; VIRION; X RAY CRYSTALLOGRAPHY;

ANTI-HIV AGENTS; COMPUTER SIMULATION; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HYDROGEN BONDING; MAGNETIC RESONANCE SPECTROSCOPY; MANNITOL; MOLECULAR STRUCTURE; PROTEIN BINDING; SULFONAMIDES; UREA;

EID: 15644376141     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960728j     Document Type: Article

References (78)

1. (a) Barré-Sinoussi, F.; Chermann, J. C.; Rey, F.; Nugeyre, M. T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vézinet-Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Isolation of a T-lymphotropic retrovirus from a patient at risk for Acquired Immune Deficiency Syndrome (AIDS). Science 1983, 220, 868-871.
2. (b) Gallo, R. C.; Sarin, P. S.; Gelman, E. P.; Robert-Guroff, M.; Richardson, E.; Kalyanaraman, V. S.; Mann, D.; Sidhu, G. D.; Stahl, R. E.; Zolla-Pazner, S.; Leibowitch, J.; Popovic, M. Isolation of Human T-Cell Leukemia Virus in Acquired Immune Deficiency Syndrome (AIDS). Science 1983, 220, 865-867.
3. (c) Clavel, F.; Guétard, D.; Brun-Vézinet, F.; Chamaret, S.; Rey, M.-A.; Santos-Ferreira, M. O.; Laurent, A. G.; Dauguet, C.; Katlama, C.; Rouzioux, C.; Klatzmann, D.: Champalimaud, J. L.; Montagnier, L. Isolation of a new retrovirus from West African patients with AIDS. Science 1986, 233, 343-346.
4. Kohl, N. E.; Emini, E. A.; Schleif, W. A.; Davis, L. J.; Heimbach, J. C.; Dixon, R. A. F.; Scolnick, E. M.; Signal, I. S. Active Human Immunodeficiency Virus Protease is Required for Viral Infectivity. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 4686-4690.
5. (a) Tomasselli, A. G.; Howe, W. J.; Sawyer, T. K.; Wlodawer, A.; Heinrikson, R. L. The Complexities of AIDS: An Assessment of the HIV Protease as a Therapeutic Target. Chim. Oggi. 1991, 9, 6-27.
6. (b) Huff, J. R. HIV Protease: A Novel Chemotherapeutic Target for AIDS. J. Med. Chem. 1991, 34, 2305-2314.
7. (c) Debouck, C. The HIV-1 Protease as a Therapeutic Target for AIDS. AIDS Res. Human Retroviruses 1992, 8, 153-164.
8. (d) Darke, P. L.; Huff, J. R. HIV Protease as an Inhibitor Target for the Treatment of AIDS. In Advances in Pharmacology; August, J. T.; Anders, M. W., Murad, F., Eds.; Academic Press: San Diego, CA, 1994; Vol. 25, pp 399-454.
9. (a) Martin, J. A. Recent Advances in the Design of HIV Protease Inhibitors. Antiviral Res. 1992, 17, 265-278.
10. (b) Wlodawer, A.; Erickson, J. W. Structure-Based Inhibitors of HIV-1 Protease Annu. Rev. Biochem. 1993, 62, 543-585.
11. (c) Thairsrivongs, S. HIV Protease Inhibitors. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic Press: San Diego, CA, 1994; Vol. 29, pp 133-144.
12. (d) De Clercq, E. Toward Improved Anti-HIV Chemotherapy: Therapeutic Strategies for Intervention with HIV Infections. J. Med. Chem. 1995, 38, 2491-2517.
13. (e) Martin, J. A.; Redshaw, S.; Thomas, G. J. Inhibitors of HIV Proteinase. In Progress in Medicinal Chemistry; Ellis, G. P., Luscombe, D. K., Eds.; Elsevier Science; New York, 1995; Vol. 32, pp 239-287.
14. 2 symmetry. J. Am. Chem. Soc. 1992, 113, 9382-9384.
15. 2 symmetry. J. Am. Chem. Soc. 1992, 113, 9382-9384.
16. 2 symmetry. J. Am. Chem. Soc. 1992, 113, 9382-9384.
17. 2 symmetry. J. Am. Chem. Soc. 1992, 113, 9382-9384.
18. 2 symmetry. J. Am. Chem. Soc. 1992, 113, 9382-9384.
19. 2 symmetry. J. Am. Chem. Soc. 1992, 113, 9382-9384.
20. 2 symmetry. J. Am. Chem. Soc. 1992, 113, 9382-9384.
21. 2 symmetry. J. Am. Chem. Soc. 1992, 113, 9382-9384.
22. 2 symmetry. J. Am. Chem. Soc. 1992, 113, 9382-9384.
23. 2 symmetry. J. Am. Chem. Soc. 1992, 113, 9382-9384.
24. 2 symmetry. J. Am. Chem. Soc. 1992, 113, 9382-9384.
25. 2 symmetry. J. Am. Chem. Soc. 1992, 113, 9382-9384.
26. 2 symmetry. J. Am. Chem. Soc. 1992, 113, 9382-9384.
27. (a) Lam, P. Y. S.; Eyermann, C. J.; Hodge, C. N.; Jadhav, P. K.; DeLucca, G. V. Patent WO 93/07128, 1993.
28. (b) Lam, P. Y. S.; Jadhav, P. K; Eyermann, C. J.; Hodge, C. N.; DeLucca, G. V.; Rodgers, J. D. Patent WO 94/19329, 1994.
29. (c) Lam, P. Y. S.; Jadhav, P. K; Eyermann, C. J.; Hodge, C. N.; Ru, Y.; Bacheler, L. T.; Meek, J. L.; Otto, M. J.; Rayner, M. M.; Wong, Y. N.; Chang, C.-H.; Weber, P. C.; Jackson, D. A.; Sharpe, T. R.; Erickson-Viitanen, S. Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors. Science 1994, 263, 380-384. For related cyclic structures, see:
30. (d) Chenera, B.; DesJarlais, R. L.; Finkelstein, J. A.; Eggleston, D. S.; Meek, T. D.; Tomaszek, T. A., Jr.; Dreyer, G. B. Nonpeptide HIV Protease Inhibitors Designed to Replace a Bound Water. Bioorg. Med. Chem. Lett. 1993, 3, 2717-2722.
31. (e) Peyman, A.; Stahl, W.; Wagner, K.; Rubbert, D.; Budt, K.-H. Non-Peptide-Based Inhibitors of Human Immunodeficiency Virus-1 Protease. Bioorg. Med. Chem. Lett. 1994, 4, 2601-2604.
32. (f) Randad, R. S.; Pan, W.; Gulnik, S. V.; Burt, S.; Erickson, J. W. De Novo Design of Nonpeptidic HIV-1 Protease Inhibitors: Incorporation of Structural Water. Bioorg. Med. Chem. Lett. 1994, 4, 1247-1252.
33. Sham, H. L.; Zhao, C.; Stewart, K. D.; Betebenner, D. A.; Lin, S.; Park, C. H.; Kong, X.-P.; Rosenbrook, W., Jr.; Herrin, T.; Madigan, D.; Vasavanonda, S.; Lyons, N.; Molla, A.; Saldivar, A.; Mersh, K. C.; McDonald, E.; Wideburg, N. E.; Denissen, J. F.; Robins, T.; Kempf, D. J.; Plattner, J. J.; Norbeck, D. W. A Novel Picomolar Inhibitor of Human Immunodeficiency Virus Type 1 Protease. J. Med. Chem. 1996, 39, 392-397.
34. (a) Tomioka, N.; Itai, A.; Iitaka, Y. A. Method for Fast Energy Estimation and Visualization of Protein-Ligand Interaction. J. Comput.-Aided Mol. Des. 1987, 1, 197-210.
35. (b) Meng, E. C.; Shoichet, B. K.; Kuntz, I. D. Automated Docking with Grid-based Energy Evaluation. J. Comput. Chem. 1992, 13, 505-524.
36. (c) Rotstein, S. H.; Murcko, M. A. GroupBuild: a Fragment-Based Method for De Novo Drug Design. J. Med. Chem. 1993, 36, 1700-1710.
37. (d) Böhm, H.-J. The Development of a Simple Empirical Scoring Function to Estimate the Binding Constant for a Protein-Ligand Complex of Known Three-Dimensional Structure. J. Comput.-Aided Mol. Des. 1994, 8, 243-256.
38. Viswanadhan, V. N.; Reddy, M. R.; Wlodawer, A.; Varney, M. D.; Weinstein, J. N. An Approach to Rapid Estimation of Relative Binding Affinities of Enzyme Inhibitors: Application to Peptidomimetic Inhibitors of the Human Immunodeficiency Virus type 1 Protease. J. Med. Chem. 1996, 39, 705-712.
39. (a) Åqvist, J.; Medina, C.; Samuelsson, J.-E. A New Method for Predicting Binding Affinity in Computer-Aided Drug Design. Protein Eng. 1994, 7, 385-391.
40. (b) Åqvist, J.; Mowbray, S. L. Sugar Recognition by a glucose/galactose receptor: evaluation of binding energetics from molecular dynamics simulations. J. Biol. Chem. 1995, 270, 9978-9981.
41. (c) Åqvist, J. Calculation of absolute binding free energies for charged ligands and the effects of long-range electrostatic interactions. J. Comput. Chem. 1996, 17, 1587-1597.
42. Hansson, T.; Åqvist, J. Estimation of Binding Free Energies for HTV Proteinase Inhibitors by Molecular Dynamics Simulations. Protein Eng. 1995, 8, 1137-1144.
43. 2-Axis of Symmetry. Tetrahedron Lett. 1991, 32, 5729-5732.
44. 2-Symmetric and Pseudosymmetric HIV-1 Protease Inhibitors from D-Mannitol and D-Arabitol. Bioorg. Med. Chem. Lett. 1991, 1, 219-222.
45. 2-Symmetric HIV-1 Protease Inhibitorsa from D-Mannitol. Bioorg. Med. Chem. Lett. 1992, 2, 353-356.
46. (d) Dreyer, G. B.; Boehm, J. C.; Chenera, B.; DesJarlais, R. L.; Hassell, A. M.; Meek, T. D.; Tomaszek, T. A., Jr.; Lewis, M. A. Symmetric Inhibitor Binds HIV-1 Protease Asymmetrically Biochemistry 1993, 32, 937-947.
47. 2-Symmetric Diols. Bioorg. Med. Chem. 1995, 3, 559-571.
48. During the preparation of this manuscript the synthesis of a series of related compounds using a similar reaction sequence was reported: Nugiel, D. A.; Jacobs, K.; Worley, T.; Patel, M.; Kaltenbach, R. F., III; Meyer, D. T.; Jadhav, P. K.; De Lucca, G. V.; Smyser, T. E.; Klabe, R. M.; Bacheler, L. T.; Rayner, M. M.; Seitz, S. P. Preparation and Structure-Activity Relationship of Novel P1/P1′-Substituted Cyclic Urea-Based Human Immunodeficiency Virus Type-1 Protease Inhibitors. J. Med. Chem. 1996, 39, 2156-2169.
49. (a) Le Merrer, Y.; Duréault, A.; Greek, C.; Micas-Languin, D.; Gravier, C.; Depezay, J.-C. Synthesis of Diepoxides and Diaziridines, Precursors of Enantiomerically Pure α-Hydroxy and α-Amino Aldehydes or Acids, from D-Mannitol. Heterocycles 1987, 25, 541-548.
50. (b) Wiggins, L. F. The Anhydrides of Polyhydric Alcohols. Part II. Derivatives of 1:2-5:6-Dianhydro Mannitol. J. Chem. Soc. 1946, 384-388.
51. (a) Sexton, A. R.; Britton, E. C. Synthesis and Identification of Propylene Glycol Phenyl Ethers. J. Am. Chem. Soc. 1948, 70, 3606-3607.
52. (b) Lipshutz, B. H.; Saumitra, S. Organocopper Reagents: Substitution, conjugate addition Carbo/Metallocupration, and other Reactions. In Organic Reactions; Paquette, L. A., Ed.; John Wiley & Sons: New York, 1992; Vol. 41, pp 135-631.
53. (c) McSweeney, G. P.; Wiggins, L. F.; Wood, D. J. C. Anhydrides of Polyhydric Alcohols. Part XVI. The Action of Phenols on Some Ethylene Oxide Derivatives. J. Chem. Soc. 1952, 37-53.
54. (a) Hughes, D. L. The Mitsunobu Reaction. In Organic Reactions; Paquette, L. A., Ed.; John Wiley & Sons: New York, 1992; Vol. 42, pp 335-656.
55. (b) Mitsunobu, O. The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products, Synthesis 1981, 1-28.
56. For a successful cyclization of a related trans-fused five-membered acetonide, see: Rossano, L. T.; Lo, Y. S.; Lee, Y.-C.; Meloni, D. J.; Moore, J. R.; Gale, T. M.; Arnett, J. F. A Practical Synthesis of Nonpeptide Cyclic Ureas as Potent HIV Protease Inhibitors. Tetrahedron Lett. 1995, 36, 4967-4970.
57. Corey, E. J.; Gras, J.-L.; Ulrich, P. A New General Method for Protection of the Hydroxyl Function. Tetrahedron Lett. 1976, 809-812.
58. (a) Sartori, E.; Caray, F.; Teulon, J. M.; Camborde, F.; Meignen, J.; Hertz, F.; Cloarec, A. Synthesis and analgesic activities of urea derivatives of α-amino-N-pyridyl benzene propanamide. Eur. J. Med. Chem. 1994, 29, 431-439.
59. (b) Staab, H. A. Reaktionsfähige Heterocyclische Diamide der Kohlensäure. Liebigs Ann. Chem. 1957, 609, 75-83.
60. Wilkerson, W. W.; Hollins, A. Y.; Cheatham, W. W.; Lam, G. N.; Erickson-Viitanen, S.; Bacheler, L.; Cordova, B. C.; Klabe, R. M.; Meek, J. L. A Bis-[N-3-(1-Hydroxy-1-Methyl-Ethyl)-Benzyl]-Cyclic Urea as a HIV Protease Inhibitor. Bioorg. Med. Chem. Lett. 1995, 5, 3027-3032.
61. For a recent report on a stereoselective synthesis of DMP 323 from D-phenylalanine and a detailed discussion on bis-N-benzylation, see: Pierce, M. E.; Harris, G. D.; Islam, Q.; Radesca, L. A.; Storace, L.; Waltermin, R. E.; Wat, E.; Jadhav, P. K.; Emmet, G. C. Stereoselective Synthesis of HIV-1 Protease Inhibitor, DMP 323. J. Org. Chem. 1996, 61, 444-450.
62. Soai, K.; Ookawa, A. Mixed Solvents Containing Methanol as Useful Reaction Media for Unique Chemoselective Reductions with Lithium Borohydride. J. Org. Chem. 1986, 51, 4000-4005.
63. (a) Arya, V. P.; Shenoy, S. J. Synthesis of New Heterocycles: Part XV-Synthesis of Novel Cyclic & Acyclic Sulphamides. Ind. J. Chem. 1976, 14B, 766-769.
64. (b) Jadhav, P. K.; Woerner, F. J. Synthesis of 8-Membered Cyclic Sulfamides: Novel HIV-1 Protease Inhibitors. Tetrahedron Lett. 1995, 36, 6383-6386.
65. Nillroth, U.; Besidsky, Y.; Classon, B.; Chattopadhyaya, J.; Ugi, I.; Danielson, U. H. Specific Interaction between HIV-1 protein-ase and 5′-phosphate peptidomimetic derivatives of nucleoside analogues. Drug. Des. Discovery 1995, 13, 43-54.
66. Sculley, M. J.; Morrison, J. F. The Determination of Kinetic Constants Governing the Slow, Tight-Binding Inhibition of Enzyme-Catalysed Reactions. Biochim. Biophys. Acta 1986, 874, 44-53.
67. (26) For a discussion on the protonation state of the catalytic aspartates, see: (a) Hyland, L. J.; Tomaszek, T. A., Jr.; Meek, T. D. Human Immunodeficiency Virus-1 Protease. 2. Use of pH Rate Studies and Solvent Kinetic Isotope Effects to Elucidate Details of Chemical Mechanism. Biochemistry 1992, 30, 8454-8463. (b) Davies, D. R. The Structure and Function of the Aspartic Proteinases. Annu. Rev. Biophys. Chem. 1990, 19, 189-215. (c) Yamazaki, T.; Nicholson, L. K.; Torchia, D. A.; Wingfield, P.; Stahl, S. J.; Kaufman, J. D.; Eyermann, C. J.; Hodge, C. N.; Lam, P. Y S.; Ru, Y.; Jadhav, P. K.; Chang, C.-H.; Weber, P. C. NMR and X-ray evidence that the HIV protease catalytic aspartyl groups are protonated in the complex formed by the protase and a non-peptide cyclic urea-based inhibitor. J. Am. Chem. Soc. 1994, 116, 10791-10792.
68. For a discussion on the protonation state of the catalytic aspartates, see: (a) Hyland, L. J.; Tomaszek, T. A., Jr.; Meek, T. D. Human Immunodeficiency Virus-1 Protease. 2. Use of pH Rate Studies and Solvent Kinetic Isotope Effects to Elucidate Details of Chemical Mechanism. Biochemistry 1992, 30, 8454-8463. (b) Davies, D. R. The Structure and Function of the Aspartic Proteinases. Annu. Rev. Biophys. Chem. 1990, 19, 189-215. (c) Yamazaki, T.; Nicholson, L. K.; Torchia, D. A.; Wingfield, P.; Stahl, S. J.; Kaufman, J. D.; Eyermann, C. J.; Hodge, C. N.; Lam, P. Y S.; Ru, Y.; Jadhav, P. K.; Chang, C.-H.; Weber, P. C. NMR and X-ray evidence that the HIV protease catalytic aspartyl groups are protonated in the complex formed by the protase and a non-peptide cyclic urea-based inhibitor. J. Am. Chem. Soc. 1994, 116, 10791-10792.
69. For a discussion on the protonation state of the catalytic aspartates, see: (a) Hyland, L. J.; Tomaszek, T. A., Jr.; Meek, T. D. Human Immunodeficiency Virus-1 Protease. 2. Use of pH Rate Studies and Solvent Kinetic Isotope Effects to Elucidate Details of Chemical Mechanism. Biochemistry 1992, 30, 8454-8463. (b) Davies, D. R. The Structure and Function of the Aspartic Proteinases. Annu. Rev. Biophys. Chem. 1990, 19, 189-215. (c) Yamazaki, T.; Nicholson, L. K.; Torchia, D. A.; Wingfield, P.; Stahl, S. J.; Kaufman, J. D.; Eyermann, C. J.; Hodge, C. N.; Lam, P. Y S.; Ru, Y.; Jadhav, P. K.; Chang, C.-H.; Weber, P. C. NMR and X-ray evidence that the HIV protease catalytic aspartyl groups are protonated in the complex formed by the protase and a non-peptide cyclic urea-based inhibitor. J. Am. Chem. Soc. 1994, 116, 10791-10792.
70. van Gunsteren, W. F.; Berendsen, H. J. C. Groningen Molecular simulation (GROMOS) Library Manual; Biomos B.V.: Groningen, 1987.
71. Markgren, P.-O.; Nillroth, U.; Lindgren, M. T.; Danielson, U. H. Inhibition of HIV-1 Proteinase by Cu2+: Evidence for high affinity complex with immobilized Cu2+ and allosteric interactions. Submitted for publication.
72. Bardsley, W. G.; McGinlay, P. B.; Roig, M. G. Optimal Design for Model Discrimination Using F-test with Non Linear Biochemical Models. Criteria for Choosing the Number and Spacing of Experimental Points. J. Theor. Biol. 1989, 139, 85-102.
73. Warshel, A.; Creighton, S. Microscopic Free Energy Calculations in Solvated Macromolecules as a Primary Structure-Function Correlator and the MOLARIS Program. In Computer simulation of biomolecular systems: theoretical and experimental approaches; van Gunsteren, W. F.; Wiener, P. K., Eds.; ESCOM Science Publishers B.V.: Leiden, 1989; pp 120-138.
74. - Interconversion Step in Human Carbonic Anhydrase I. J. Am. Chem. Soc. 1993, 115, 631-635.
75. Berendsen, H. J. C.; Postma, J. P. M.; van Gunsteren, W. F.; Hermans, J. Interaction Models for Water in Relation to Protein Hydration. In Intermolecular Forces; Pullman, B., Ed.; Reidel: Dordrecht, 1981; pp 331-342.
76. King, G.; Warshel, A. A Surface Constrained All-Atom Solvent Model for Effective Simulations of Polar Solutions. J. Chem Phys. 1989, 91, 3647-3661.
77. Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M. Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MacroModel-An Integrated Software System for Modeling Organic and Bioorganic Molecules Using Molecular Mechanics. J. Comput. Chem. 1990, 11, 440-467.
78. Åqvist, J.; Hansson, T. On the Validity of Electrostatic Linear Response in Polar Solvents. J. Phys. Chem. 1996, 100, 9512-9521.